Surmodics, Inc. revised earnings guidance for the fiscal year ending September 30, 2023. The company now expects fiscal year 2023 total revenue to range from $130 million to $132 million, representing an increase of 30% to 32% compared to the 2022. The company?s prior guidance called for fiscal year 2023 total revenue of $103 million to $106 million, representing an increase of 3% to 6% compared to the 2022.

The company now expects fiscal 2023 GAAP diluted loss per share to range from $0.55 to $0.40. The company?s prior guidance called for fiscal 2023 GAAP diluted loss per share of $2.30 to $2.00.